Evidence lead: Bottom-seven record · Low appeal-filing share
AultCare MA: Only a small share of denials entered appeal
239 appeals correspond to 15.0% of the plan's denied requests. That is rank #37 of 37 for filing share. The ratio reports aggregate activity; it cannot reveal why an appeal was or was not filed, whether the underlying cases were comparable, or what happened outside the reporting window.
Bottom-seven record · Low appeal-filing share
Only a small share of denials entered appeal
239 appeals correspond to 15.0% of the plan's denied requests. That is rank #37 of 37 for filing share. The ratio reports aggregate activity; it cannot reveal why an appeal was or was not filed, whether the underlying cases were comparable, or what happened outside the reporting window.
Bottom-seven record · Smaller request-volume cohort
One of the narrower authorization records
The source records 29,000 requests here, placing the contract in the smallest-volume tier. Its request-volume rank is #36 of 37. Volume shows the denominator behind approvals and denials; it is not a measure of plan quality, membership, benefit breadth, price, or future coverage decisions.
Bottom-seven record · Lower denial-rate cohort
One of the ten lowest denial rates
AultCare MA's 5.5% rate belongs to the lowest-denial tier in this table. The exact rank is #31 of 37. This is aggregate prior-authorization activity for the reporting window, not a probability that a particular service, drug, or beneficiary request will be denied.
Ranks seven through ten · High overturn-rate cohort
One of the ten highest appeal overturn rates
75.0% of this contract's filed appeals were overturned in the source record. Its overturn-rate rank is #10 of 37. The denominator is filed appeals, not all authorization requests. The percentage therefore describes reviewed appeals and must not be read as an individual outcome forecast.
Ranks eleven through fifteen · Upper-middle reversal reach
Reversals covered an above-median share of denials
Overturned appeals represent 11.2% of all denials here, based on 179 reversals. The cross-contract rank is #11 of 37. This derived measure combines appeal filing and outcome, so it supplies scale context but does not identify clinical reasons, administrative errors, or coverage rules.